EAEU Market

Eurasian Pharma Register Cannot Be Used to Disqualify Tender Bids

A significant ruling for Russian pharmaceutical distributors: The Arbitration Court of the Bryansk Region has sided with a supplier in a dispute with the...

New FMBA Radiopharmaceutical ‘Rakurs’ Introduced into Clinical Practice

Russian nuclear medicine has received a new tool for fighting cancer. The drug "Rakurs, 223Ra", developed by FMBA specialists, has passed state registration and...
spot_imgspot_img

Russian Pharma Market: Key GMP Certification Trends

Pharmaceutical manufacturing is one of the most regulated industries in the world. The price of error here is patient...

Import Substitution in Veterinary Medicine: VGNKI Registers 4.5 Times More Domestic Drugs Than Foreign Ones in 2025

The VGNKI (Russian State Center for Quality and Standardization of Veterinary Drugs and Feed) presented statistics for 2025, confirming a dramatic market shift. The institution, subordinate to Rosselkhoznadzor, continues to filter the market, allowing only proven effective remedies into circulation.

GEROPHARM and R-PHARM Pharmaceutical Plant in Azerbaijan Sign Partnership Agreement for Insulin Localisation

GEROPHARM and OOO “R-Pharm” (member of R-Pharm Group of Companies) have announced a strategic partnership to localise the production of medicines for the treatment of socially significant diseases in Azerbaijan.

Pharmaceutical Drug Production in Russia (June, January–June 2023)

In January–June 2023, Russian manufacturers produced 342.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 2.6% from the same period in 2022.

RNC Pharma: Pharmaceutical Drug Production in Russia (May 2023)

In January–May 2023, Russian manufacturers produced 282 billion rubles’ of pharmaceutical drugs (manufacturer’s prices, VAT included), down 5.8% from the same period in 2022.

RNC Pharma: Top 20 Online Pharmaceutical Retailers in Russia in Q1 2023

In January–March 2023, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 80.2 billion rubles (end-user prices, VAT included), up 2.3% from January–March 2022 (against 69.6% in Q1 2022, with its rush demand).